Iterum Therapeutics (ITRM) cae 38,62% en una sucesión de 12 días en pérdidas, déficit de ingresos, riesgos de cumplimiento de Nasdaq

The share price fell to its lowest level so far this month, with an intraday gain of 0.00%.

Iterum Therapeutics (ITRM) faces mounting pressure as its stock continues a 12-day losing streak, declining 38.62% over the period. The company is under Nasdaq compliance scrutiny for failing to meet both the $35 million market value threshold and the $1.00 minimum bid price requirement, with delisting risks looming if it cannot resolve these issues by June 2026 and February 2026, respectively. Financial challenges persist, with Q3 2025 results revealing a $9 million net loss and a $0.16 EPS deficit, widening from prior periods despite modest revenue from its FDA-approved drug Orlyvah.

Orlyvah’s commercial launch has generated 280+ prescriptions and $400,000 in initial sales, but this remains far below management’s $5–15 million 2026 revenue forecast. Analysts remain divided, with H.C. Wainwright assigning a $9.00 price target while others flag poor technical momentum and weak fundamentals. The stock’s valuation metrics, including a -6,913% net profit margin and -285.48% TTM ROI, underscore its precarious financial position.

With operating expenses outpacing projected revenues and reliance on capital raises, Iterum’s ability to sustain operations and regain compliance hinges on Orlyvah’s market acceptance and decisive cost management.